Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Fortin, Patricia M ^a   Tejani, Aaron M ^a   Bassett, Ken ^a   Musini, Vijaya M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOGLOBULIN; PREDNISOLONE; GLUCOCORTICOID; IMMUNOLOGIC FACTOR;

ADJUVANT THERAPY; ALL CAUSE MORTALITY; DISEASE ACTIVITY SCORE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; REMISSION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; WEGENER GRANULOMATOSIS; ADJUVANT CHEMOTHERAPY; ADULT; DRUG COMBINATION; MAINTENANCE CHEMOTHERAPY; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AZATHIOPRINE; CHEMOTHERAPY, ADJUVANT; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MAINTENANCE CHEMOTHERAPY; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEGENER GRANULOMATOSIS;

MLCS; MLOWN;

EID: 84874807920     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007057.pub3     Document Type: Review

References (19)

1. Jayne DRW, Chapel, H, Adu, D, Misbah, S, ODonoghue, D, Scott, D, Lockwood, CM. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Quarterly Journal of Medicine 2000;93:433-9.
2. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al.Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. Journal of the American Society of Nephrology 2004;15(3):717-21.
3. Chung SA, Seo P. Advances in the use of biologic agents for the treatment of systemic vasculitis. Current Opinion in Rheumatology 2009;21:3-9.
4. Cohen RD, Conn DL, Ilstrup DM. Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clinic Proceedings 1980;55(3):146-55.
5. de Groot K, Adu D, Savage CO, EUVAS (European vasculitis study group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrology Dialysis Transplantation 2001;16(10):2018-27.
6. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al.Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and Rheumatism 2005;52(8):2461-9.
7. Esper GJ, Johnson JS. Update on the treatment of Wegener's granulomatosis. Bulletin on the Rheumatic Diseases. 1999;48(11):1-4.
8. Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener's granulomatosis. Current Opinion in Rheumatology 2006;18(1):25-32.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
10. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al.Wegener's granulomatosis: an analysis of 158 patients. Annals of Internal Medicine 1992;116(6):488-98.
11. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al.A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. New England Journal of Medicine 2003;349(1):36-44.
12. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al.Birmingham Vasculitis Activity Score in systemic necrotizing vasculitis. QJM 1994;87(11):671-8.
13. Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Annals of Internal Medicine 1995;123(12):925-32.
14. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, et al.An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis and Rheumatism 2000;43(5):1021-32.
15. Scott DG, Watts, RA. Systemic Vasculitis: epidemiology, classification, and environmental factors. Annals of the Rheumatic Diseases 2000;59(3):161-3.
16. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. New England Journal of Medicine 1996;335(1):16-20.
17. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. New England Journal of Medicine 2005;352(4):351-61.
18. Wung PK, Stone JH. Therapeutics of Wegener's granulomatosis. Nature Clinical Practice Rheumatology 2006;2(4):192-200.
19. Fortin PM, Tejani AM, Bassett K, Musini VM. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007057.pub2]